Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma

Radiation Oncology

Table 2 Treatment after recurrence

Case number	PFS duration (months)	First site of recurrence	Number of treatments after recurrence
Case number	PFS duration (months)	First site of recurrence	Surgery	C-ion RT	RFA	TACE	TAI	Molecular targeted therapy
1	1.7	Intrahepatic recurrence	None	None	None	2	None	None
2^a	50.9	Distant metastases (lung)	None	1	None	None	None	1 (Lenvatinib)
3	9.5	Intrahepatic recurrence	None	None	None	1	None	1 (Sorafenib)
4	24.7	No recurrence	None	None	None	None	None	None
5	9.3	Intrahepatic recurrence	1	None	1	3	None	2 (Sorafenib and Lenvatinib)
6^b	12.2	Distant metastases (lung)	1	1	1	None	1	None
7	3.6	Intrahepatic recurrence	None	None	1	None	None	1 (Sorafenib)
8	8.6	Intrahepatic recurrence	None	None	1	None	None	1 (Sorafenib)
9	1.2	Intrahepatic recurrence	None	None	None	1	None	1 (Lenvatinib)
10	2.1	Intrahepatic recurrence	None	None	None	1^c	None	None
11	1.8	Local recurrence	None	None	None	None	None	None

^aPatient in Case 2 had local recurrence after distant metastases to the lung and received C-ion RT for local recurrence as a re-irradiation
^bPatient in Case 6 had intrahepatic recurrence outside the target region after distant metastases to the lung, who received surgery for the lung metastases and C-ion RT for the intrahepatic recurrence
^cPatient in Case 10 received transarterial embolization
^¶Abbreviations: C-ion RT carbon ion radiotherapy, PFS progression-free survival, RFA percutaneous radiofrequency ablation, TACE transarterial chemoembolization, TAI transcatheter arterial infusion chemotherapy

ISSN: 1748-717X